Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response...

Descripción completa

Detalles Bibliográficos
Autores: Iznardo, Helena|||0000-0002-0710-5521, Roé Crespo, Esther|||0000-0003-1601-9227, Serra Baldrich, Esther|||0000-0001-7603-0300, Puig Sanz, Lluís|||0000-0001-6083-0952
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:272884
Acceso en línea:https://ddd.uab.cat/record/272884
https://dx.doi.org/urn:doi:10.3390/pharmaceutics15020385
Access Level:acceso abierto
Palabra clave:Abrocitinib
Jak inhibitor
JAK1
Atopic dermatitis
id ES_917cf8d9264eaea36ebbb6ae2a0f8c2b
oai_identifier_str oai:ddd.uab.cat:272884
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic DermatitisIznardo, Helena|||0000-0002-0710-5521Roé Crespo, Esther|||0000-0003-1601-9227Serra Baldrich, Esther|||0000-0001-7603-0300Puig Sanz, Lluís|||0000-0001-6083-0952AbrocitinibJak inhibitorJAK1Atopic dermatitisAbrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62.9% (95% CrI 42.5-79.9%) for abrocitinib 200 mg and 43.0% (95% CrI 24.8-64.0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/272884https://dx.doi.org/urn:doi:10.3390/pharmaceutics15020385reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2728842026-06-06T12:50:31Z
dc.title.none.fl_str_mv Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
title Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
spellingShingle Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Iznardo, Helena|||0000-0002-0710-5521
Abrocitinib
Jak inhibitor
JAK1
Atopic dermatitis
title_short Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
title_full Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
title_fullStr Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
title_full_unstemmed Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
title_sort Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
dc.creator.none.fl_str_mv Iznardo, Helena|||0000-0002-0710-5521
Roé Crespo, Esther|||0000-0003-1601-9227
Serra Baldrich, Esther|||0000-0001-7603-0300
Puig Sanz, Lluís|||0000-0001-6083-0952
author Iznardo, Helena|||0000-0002-0710-5521
author_facet Iznardo, Helena|||0000-0002-0710-5521
Roé Crespo, Esther|||0000-0003-1601-9227
Serra Baldrich, Esther|||0000-0001-7603-0300
Puig Sanz, Lluís|||0000-0001-6083-0952
author_role author
author2 Roé Crespo, Esther|||0000-0003-1601-9227
Serra Baldrich, Esther|||0000-0001-7603-0300
Puig Sanz, Lluís|||0000-0001-6083-0952
author2_role author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Abrocitinib
Jak inhibitor
JAK1
Atopic dermatitis
topic Abrocitinib
Jak inhibitor
JAK1
Atopic dermatitis
description Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62.9% (95% CrI 42.5-79.9%) for abrocitinib 200 mg and 43.0% (95% CrI 24.8-64.0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/272884
https://dx.doi.org/urn:doi:10.3390/pharmaceutics15020385
url https://ddd.uab.cat/record/272884
https://dx.doi.org/urn:doi:10.3390/pharmaceutics15020385
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413394610651136
score 15,811543

Similares en LA Referencia